The lived experience of interferon-free treatments for hepatitis C: A thematic analysis

International Journal of Drug Policy

Volumn 38, Issue , 2016, Pages 21-28

  Whiteley, David ^a,b,c   Whittaker, Anne ^b,c   Elliott, Lawrie ^d   Cunningham Burley, Sarah ^e  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^c ASTLEY AINSLIE HOSPITAL   (United Kingdom)

^d GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antiviral agents; Hepatitis C; Interferon free; Lived experience; Qualitative research; Therapeutics

Indexed keywords

DACLATASVIR; DASABUVIR; GLECAPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PIBRENTASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; EXPECTATION; FEAR; FEMALE; GUILT; HEALTH BELIEF; HEPATITIS C; HUMAN; MALE; PERSONAL EXPERIENCE; PHENOMENOLOGY; PLEASURE; PRIORITY JOURNAL; PURPOSIVE SAMPLE; SCOTLAND; SEMI STRUCTURED INTERVIEW; THEMATIC ANALYSIS; UNIVERSITY HOSPITAL; INTERVIEW; MIDDLE AGED; PSYCHOLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; SCOTLAND; YOUNG ADULT;

EID: 84995387893     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2016.10.013     Document Type: Article

References (51)

1. Ajiboye, O., Social phenomenology of Alfred Schütz and the development of African sociology. British Journal of Arts and Social Sciences 4 (2012), 12-25.
2. Alavi, M., Grebely, J., Micallef, M., Dunlop, A.J., Balcomb, A.C., Day, C.A., et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clinical Infectious Diseases 57:Suppl. 2 (2013), S62-S69.
3. Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M., Marcellin, P., Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives. Liver International 36:Suppl. 1 (2016), 47-57.
4. Barsky, A., Saintfort, R., Rogers, M., Borus, J., Nonspecific medication side effects and the nocebo phenomenon. JAMA 287 (2002), 622-627.
5. Batchelder, A.W., Peyser, D., Nahvi, S., Arnsten, J.H., Litwin, A.H., Hepatitis C treatment turned me around: Psychological and behavioural transformation related to hepatitis C treatment. Drug and Alcohol Dependence 153 (2015), 66-71.
6. Braun, V., Clarke, V., Using thematic analysis in psychology. Qualitative Research in Psychology 3 (2006), 77-101.
7. Brew, I., Butt, C., Wright, N., Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care? A narrative systematic review of the evidence base. British Journal of General Practice 63 (2013), e842-e851.
8. Chung, R.T., Baumert, T.F., Curing chronic hepatitis C—The arc of a medical triumph. New England Journal of Medicine 370 (2014), 1576-1578.
9. Clark, J.A., Gifford, A.L., Resolute efforts to cure hepatitis C: Understanding patients’ reasons for completing antiviral treatment. Health 19 (2014), 473-489.
10. Coppola, N., Martini, S., Pisaturo, M., Sagnelli, C., Filippini, P., Sagnelli, E., Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World Journal of Virology 4 (2015), 1-12.
11. Crawford, S., Bath, N., Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clinical Infectious Diseases 57:Suppl. 2 (2013), S75-S79.
12. Faasse, K., Petrie, K., The nocebo effect: Patient expectations and medication side effects. Postgraduate Medical Journal 89 (2013), 540-546.
13. Ford, N., Wiktor, S., Kaplan, K., Andrieux-Meyer, I., Hill, A., Radhakrishnan, P., et al. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. International Journal of Drug Policy 26 (2015), 1088-1093.
14. Fraenkel, L., McGraw, S., Wongcharatrawee, S., Garcia-Tsao, G., Patients’ experiences related to anti-viral treatment for hepatitis C. Patient Education and Counseling 62 (2006), 148-155.
15. Fung, J., Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. World Journal of Hepatology 7 (2015), 2543-2550.
16. Goodacre, L., Goodacre, J., Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication. Rheumatology 43 (2004), 583-586.
17. Gradishar, W., No pain, no gain: A fallacy so far. Journal of Clinical Oncology 33 (2015), 235-237.
18. Grebely, J., Alavi, M., Micallef, M., Dunlop, A.J., Balcomb, A.C., Phung, N., et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS study. Addiction 111 (2016), 311-319.
19. Healthcare Improvement Scotland and NHS National Services Scotland, National clinical guidelines for the treatment of HCV in adults: Version 2. 2015 Retrieved 22 July 2016 from http://www.documents.hps.scot.nhs.uk/bbvsti/hepatitis-c/guidance/national-clinical-guidelines-treatment-hepatitis-c-in-adults-2015.pdf.
20. Hopwood, M., Treloar, C., The experience of interferon-based treatments for hepatitis C infection. Qualitative Health Research 15 (2005), 635-646.
21. Janke, E., McGraw, S., Garcia-Tsao, G., Fraenkel, L., Psychosocial issues in hepatitis C: A qualitative analysis. Psychosomatics 49 (2008), 494-501.
22. Keats, J., Micallef, M., Grebely, J., Hazelwood, S., Everingham, H., Shrestha, N., et al. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy 26 (2015), 999-1006.
23. Kinder, M., The lived experience of treatment for hepatitis C. Gastroenterology Nursing 32 (2009), 401-408.
24. Lam, B., Jeffers, T., Younoszai, Z., Fazel, Y., Younossi, Z., The changing landscape of hepatitis C virus therapy: Focus on interferon-free treatment. Therapeutic Advances in Gastroenterology 8 (2015), 298-312.
25. Litwin, A., Harris, K., Nahvi, S., Zamor, P., Soloway, I.J., Tenore, P.L., et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse & Treatment 37 (2009), 32-40.
26. Lorish, C., Richards, B., Brown, S., Perspective of the patient with rheumatoid arthritis on issues related to missed medication. Arthritis Care & Research 3 (1990), 78-84.
27. Mason, J., Qualitative researching. 2nd ed., 2002, Sage Publications Ltd., London.
28. McGowan, C.E., Monis, A., Bacon, B.R., Mallolas, J., Goncalse, F.L., Goulis, I., et al. A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. Hepatology 57 (2013), 1325-1332.
29. Patton, M., Qualitative research and evaluation methods: Integrating theory and practice. 4th ed., 2015, Sage Publications, London.
30. Pawlotsky, J.-M., Feld, J., Zeuzem, S., Hoofnagle, J., From non-A, non-B hepatitis to hepatitis C virus cure. Journal of Hepatology 62:Suppl. 1 (2015), S87-S99.
31. Rance, J., Treloar, C., on behalf of the ETHOS Study Group, Not just methadone Tracy: Transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction 109 (2014), 452-459.
32. Reau, N.S., Jensen, D.M., Sticker shock and the price of new therapies for hepatitis C: Is it worth it?. Hepatology 59 (2014), 1246-1249.
33. Rice, J., Burnett, D., Tsotsis, H., Lindstrom, M.J., Cornett, D.D., Voermans, P., et al. Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology 56 (2012), 1252-1260.
34. Ritzer, G.J., Ryan, M., The concise encyclopedia of sociology. 2011, Wiley-Blackwell, Chichester, West Sussex.
35. Schütz, A. (1967). The phenomenology of the social world (G. Walsh & F. Lehnert, Trans.). London: Heinemann Educational Books.
36. ®) SMC No. (1002/14). 2014 Retrieved 22nd July 2016 from https://www.scottishmedicines.org.uk/files/advice/daclatasvir_Daklinza_FINAL_Oct_2014_Updated_30.10.14_for_website.pdf.
37. ®) SMC No. (1030/15). 2015 Retrieved 22nd July 2016 from https://www.scottishmedicines.org.uk/files/advice/ledipasvir_sofosbuvir_Harvoni_FINAL_February_2015_for_website.pdf.
38. ®) film-coated tablets SMC No. (1051/15). 2015 Retrieved 22nd July 2016 from https://www.scottishmedicines.org.uk/files/advice/ombitasvir__Viekirax__plus_dasabuvir_FINAL_May_2015_for_website.pdf.
39. Sgorbini, M., O'Brien, L., Jackson, D., Living with hepatitis C and treatment: The personal experiences of patients. Journal of Clinical Nursing 18 (2009), 2282-2291.
40. Shaw, J., Connelly, D., Phenomenology and physiotherapy: Meaning in research and practice. Physical Therapy Reviews 17 (2012), 398-408.
41. Sheppard, K., Hubbert, A., The patient experience of treatment for hepatitis C. Gastroenterology Nursing 29 (2006), 309-315.
42. Taylor-Young, P., Hildebrandt, E., The multidimensional burden of hepatitis C and its treatment: A case study. Gastroenterology Nursing 32 (2009), 180-187.
43. Treloar, C., Rance, J., Bath, N., Everingham, H., Micallef, M., Day, C., et al. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy 26 (2015), 992-998.
44. Trusson, D., Pilnick, A., The role of hair loss in cancer identity: Perceptions of chemotherapy-induced alopecia among women treated for early-stage breast cancer or ductal carcinoma in situ. Cancer Nursing, 39, 2016, 10.1097/NCC.0000000000000373 [Epub ahead of print].
45. UK Medicines Information, New drugs online report for glecaprevir + pibrentasvir., 2016 Retrieved 22nd July 2016 from http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6772.
46. Whiteley, D., Elliott, L., Cunningham-Burley, S., Whittaker, A., Health-related quality of life for individuals with hepatitis C: A narrative review. International Journal of Drug Policy 26 (2015), 936-949.
47. Wolfe, D., Luhmann, N., Harris, M., Momenghalibaf, A., Albers, E., Byrne, J., et al. Human rights and access to hepatitis C treatment for people who inject drugs. International Journal of Drug Policy 26 (2015), 1072-1080.
48. Younossi, Z.M., Stepanova, M., Nader, F., Lam, B., Hunt, S., The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: A study of health-related quality of life. Aliment Pharmacology & Therapeutics 42 (2015), 286-295.
49. Younossi, Z.M., Stepanova, M., Sulkowski, M., Naggie, S., Puoti, M., Orkin, C., et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: The impact on patient-reported outcomes. Journal of Infectious Diseases 212 (2015), 367-377.
50. Younossi, Z.M., Stepanova, M., Afdhal, N., Kowdley, K.V., Zeuzem, S., Henry, L., et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. Journal of Hepatology 63 (2015), 337-345.
51. Zickmund, S.L., Bryce, C.L., Blasiole, J.A., Shinkunas, L., LaBrecque, D.R., Arnold, R.M., Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. European Journal of Gastroenterology & Hepatology 18 (2006), 381-388.